JP2020505433A - Ｈｓｐ９０阻害剤を使用してがんを治療するための方法 - Google Patents

Ｈｓｐ９０阻害剤を使用してがんを治療するための方法 Download PDF

Info

Publication number
JP2020505433A
JP2020505433A JP2019542191A JP2019542191A JP2020505433A JP 2020505433 A JP2020505433 A JP 2020505433A JP 2019542191 A JP2019542191 A JP 2019542191A JP 2019542191 A JP2019542191 A JP 2019542191A JP 2020505433 A JP2020505433 A JP 2020505433A
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
bcl
hsp90 inhibitor
hsp90
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019542191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505433A5 (enExample
Inventor
ビーハリー，ニール
ヘルナンデス，メアリーレンズ
ランドレット，ショーン
シュイ，ティエン
ロスバーグ，ジョナサン・エム
リチェンステイン，ヘンリ
Original Assignee
エイアイ・セラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイアイ・セラピューティクス・インコーポレーテッド filed Critical エイアイ・セラピューティクス・インコーポレーテッド
Publication of JP2020505433A publication Critical patent/JP2020505433A/ja
Publication of JP2020505433A5 publication Critical patent/JP2020505433A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019542191A 2017-02-03 2018-02-01 Ｈｓｐ９０阻害剤を使用してがんを治療するための方法 Withdrawn JP2020505433A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762454113P 2017-02-03 2017-02-03
US62/454,113 2017-02-03
US201762563991P 2017-09-27 2017-09-27
US62/563,991 2017-09-27
US201762587886P 2017-11-17 2017-11-17
US62/587,886 2017-11-17
PCT/US2018/016361 WO2018144680A1 (en) 2017-02-03 2018-02-01 Methods for treating cancer using hsp90 inhibitors

Publications (2)

Publication Number Publication Date
JP2020505433A true JP2020505433A (ja) 2020-02-20
JP2020505433A5 JP2020505433A5 (enExample) 2021-03-11

Family

ID=63038389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542191A Withdrawn JP2020505433A (ja) 2017-02-03 2018-02-01 Ｈｓｐ９０阻害剤を使用してがんを治療するための方法

Country Status (13)

Country Link
US (2) US10799508B2 (enExample)
EP (1) EP3576794A1 (enExample)
JP (1) JP2020505433A (enExample)
KR (1) KR20190110128A (enExample)
CN (1) CN110536702A (enExample)
AU (1) AU2018215336A1 (enExample)
BR (1) BR112019016024A2 (enExample)
CA (1) CA3052594A1 (enExample)
IL (1) IL268430A (enExample)
MX (1) MX2019009227A (enExample)
RU (1) RU2019127350A (enExample)
TW (1) TW201840337A (enExample)
WO (1) WO2018144680A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542326A (ja) * 2020-09-17 2023-10-06 アルベルト・アインシュタイン・カレッジ・オブ・メディシン Ｂａｘ活性化剤を用いた併用療法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505433A (ja) 2017-02-03 2020-02-20 エイアイ・セラピューティクス・インコーポレーテッド Ｈｓｐ９０阻害剤を使用してがんを治療するための方法
BR112020006009A2 (pt) * 2017-09-27 2020-10-06 Al Therapeutics, Inc. métodos terapêuticos relacionados a inibidores de hsp90
BR112021007823A2 (pt) * 2018-11-08 2021-07-27 Glaxosmithkline Intellectual Property Development Limited combinação de inibidores da prmt5 e inibidores do bcl-2
AU2020214802A1 (en) 2019-01-29 2021-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2022540317A (ja) * 2019-06-25 2022-09-15 ターベダ セラピューティクス インコーポレイテッド Ｈｓｐ９０結合コンジュゲートおよびその併用療法
PH12022551091A1 (en) 2019-11-05 2024-06-24 Abbvie Deutschland Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021157650A1 (ja) * 2020-02-05 2021-08-12 カルナバイオサイエンス株式会社 抗がん剤組成物
KR102683903B1 (ko) * 2020-09-16 2024-07-12 한국원자력의학원 아리피프라졸을 유효성분으로 함유하는 bcl2 저해제의 항암 효과 증진용 조성물
CN116615195A (zh) * 2020-09-17 2023-08-18 阿尔伯爱因斯坦医学院 使用bax激活剂的组合治疗
WO2023060137A2 (en) * 2021-10-05 2023-04-13 Board Of Regents, The University Of Texas System Methods and compositions comprising b7-h3 binding polypeptides
CN114588269B (zh) * 2022-04-06 2023-06-27 宁波大学附属人民医院 Bcl-2抑制剂和HDAC抑制剂的组合物及其用途
WO2024006292A2 (en) * 2022-06-27 2024-01-04 Foghorn Therapeutics Inc. Methods of treating cancer
CN115957328A (zh) * 2022-07-13 2023-04-14 杭州百可生物科技有限公司 一种用于治疗白血病的药物组合物以及白血病的治疗方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060253A2 (en) 2009-11-13 2011-05-19 Myrexis, Inc. Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
CN103002895A (zh) * 2010-02-12 2013-03-27 尼基制药公司 治疗血液癌症的方法
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
NZ618062A (en) * 2011-04-28 2016-04-29 Sloan Kettering Inst Cancer Hsp90 combination therapy
JP2020505433A (ja) 2017-02-03 2020-02-20 エイアイ・セラピューティクス・インコーポレーテッド Ｈｓｐ９０阻害剤を使用してがんを治療するための方法
BR112020006009A2 (pt) 2017-09-27 2020-10-06 Al Therapeutics, Inc. métodos terapêuticos relacionados a inibidores de hsp90

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542326A (ja) * 2020-09-17 2023-10-06 アルベルト・アインシュタイン・カレッジ・オブ・メディシン Ｂａｘ活性化剤を用いた併用療法

Also Published As

Publication number Publication date
RU2019127350A (ru) 2021-03-03
TW201840337A (zh) 2018-11-16
WO2018144680A1 (en) 2018-08-09
KR20190110128A (ko) 2019-09-27
RU2019127350A3 (enExample) 2021-05-31
MX2019009227A (es) 2020-02-12
CN110536702A (zh) 2019-12-03
US20210030759A1 (en) 2021-02-04
CA3052594A1 (en) 2018-08-09
US10799508B2 (en) 2020-10-13
EP3576794A1 (en) 2019-12-11
IL268430A (en) 2019-09-26
US20180221376A1 (en) 2018-08-09
BR112019016024A2 (pt) 2020-03-31
AU2018215336A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
US10799508B2 (en) Methods for treating cancer using HSP90 inhibitors
US20200253979A1 (en) Therapeutic methods relating to hsp90 inhibitors
US11266654B2 (en) Apilimod compositions and methods for using same
CN107249638B (zh) 阿匹莫德用于治疗肾癌
JP2020525427A (ja) 癌を処置するための方法
TWI746449B (zh) 使用阿吡莫德治療癌症之方法
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
WO2013059320A1 (en) Treatment of cancers with mutant npm1 with mek inhibitors
NZ722491B2 (en) Apilimod compositions and methods for using same
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210121

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220517